Cargando…

Biochemical comparison of four commercially available C1 esterase inhibitor concentrates for treatment of hereditary angioedema

BACKGROUND: For safe and efficacious treatment of hereditary angioedema, C1 esterase inhibitor (C1-INH) concentrates should have high purity and high amounts of functional protein. As no pharmacopoeia requirements exist for C1-INH concentrate lot release, biochemical characteristics as declared by t...

Descripción completa

Detalles Bibliográficos
Autores principales: Feussner, Annette, Kalina, Uwe, Hofmann, Peter, Machnig, Thomas, Henkel, Georg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4285325/
https://www.ncbi.nlm.nih.gov/pubmed/24805006
http://dx.doi.org/10.1111/trf.12678
_version_ 1782351570203049984
author Feussner, Annette
Kalina, Uwe
Hofmann, Peter
Machnig, Thomas
Henkel, Georg
author_facet Feussner, Annette
Kalina, Uwe
Hofmann, Peter
Machnig, Thomas
Henkel, Georg
author_sort Feussner, Annette
collection PubMed
description BACKGROUND: For safe and efficacious treatment of hereditary angioedema, C1 esterase inhibitor (C1-INH) concentrates should have high purity and high amounts of functional protein. As no pharmacopoeia requirements exist for C1-INH concentrate lot release, biochemical characteristics as declared by the manufacturers may not be compared directly. This study compared the characteristics and purity profiles of four commercially available C1-INH concentrates. STUDY DESIGN AND METHODS: The analysis included one transgenic (Ruconest) and three plasma-derived (Berinert, Cetor, Cinryze) C1-INH concentrates. C1-INH antigen concentration was determined by nephelometry, total protein (specific activity) with a Bradford assay, purity by size-exclusion chromatography and gel electrophoresis, and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry was performed. RESULTS: Functionality (inversely proportional to antigen-to-activity ratio) was lowest for Ruconest (1.67), followed by Cetor (1.42), Berinert (1.24), and Cinryze (1.22). Specific activity (U/mg) and purity (%) were highest in Ruconest (12.13; 98.6) and Berinert (11.57; 97.0), followed by Cinryze (10.41; 89.5) and Cetor (9.01; 88.6). Main protein bands were found for all plasma-derived products at approximately 105 kDa, and for Ruconest, at approximately 98 kDa. Additional bands in the plasma-derived products were α1-antichymotrypsin, ceruloplasmin, Factor C3 (Cinryze/Cetor), and immunoglobulin heavy constant mu (Berinert). CONCLUSION: Ruconest has a very high purity profile but is not identical to the human C1-INH protein. Of the plasma-derived products, Berinert has the highest purity profile. The impact of the nontherapeutic proteins identified has not yet been evaluated. For harmonization of the analysis for drug release, we recommend the establishment of regulatory requirements for purity determination and the implementation of threshold levels in C1-INH concentrates.
format Online
Article
Text
id pubmed-4285325
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BlackWell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-42853252015-01-26 Biochemical comparison of four commercially available C1 esterase inhibitor concentrates for treatment of hereditary angioedema Feussner, Annette Kalina, Uwe Hofmann, Peter Machnig, Thomas Henkel, Georg Transfusion Blood Components BACKGROUND: For safe and efficacious treatment of hereditary angioedema, C1 esterase inhibitor (C1-INH) concentrates should have high purity and high amounts of functional protein. As no pharmacopoeia requirements exist for C1-INH concentrate lot release, biochemical characteristics as declared by the manufacturers may not be compared directly. This study compared the characteristics and purity profiles of four commercially available C1-INH concentrates. STUDY DESIGN AND METHODS: The analysis included one transgenic (Ruconest) and three plasma-derived (Berinert, Cetor, Cinryze) C1-INH concentrates. C1-INH antigen concentration was determined by nephelometry, total protein (specific activity) with a Bradford assay, purity by size-exclusion chromatography and gel electrophoresis, and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry was performed. RESULTS: Functionality (inversely proportional to antigen-to-activity ratio) was lowest for Ruconest (1.67), followed by Cetor (1.42), Berinert (1.24), and Cinryze (1.22). Specific activity (U/mg) and purity (%) were highest in Ruconest (12.13; 98.6) and Berinert (11.57; 97.0), followed by Cinryze (10.41; 89.5) and Cetor (9.01; 88.6). Main protein bands were found for all plasma-derived products at approximately 105 kDa, and for Ruconest, at approximately 98 kDa. Additional bands in the plasma-derived products were α1-antichymotrypsin, ceruloplasmin, Factor C3 (Cinryze/Cetor), and immunoglobulin heavy constant mu (Berinert). CONCLUSION: Ruconest has a very high purity profile but is not identical to the human C1-INH protein. Of the plasma-derived products, Berinert has the highest purity profile. The impact of the nontherapeutic proteins identified has not yet been evaluated. For harmonization of the analysis for drug release, we recommend the establishment of regulatory requirements for purity determination and the implementation of threshold levels in C1-INH concentrates. BlackWell Publishing Ltd 2014-10 2014-05-08 /pmc/articles/PMC4285325/ /pubmed/24805006 http://dx.doi.org/10.1111/trf.12678 Text en © 2014 The Authors. Transfusion published by Wiley Periodicals, Inc. on behalf of AABB. http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Blood Components
Feussner, Annette
Kalina, Uwe
Hofmann, Peter
Machnig, Thomas
Henkel, Georg
Biochemical comparison of four commercially available C1 esterase inhibitor concentrates for treatment of hereditary angioedema
title Biochemical comparison of four commercially available C1 esterase inhibitor concentrates for treatment of hereditary angioedema
title_full Biochemical comparison of four commercially available C1 esterase inhibitor concentrates for treatment of hereditary angioedema
title_fullStr Biochemical comparison of four commercially available C1 esterase inhibitor concentrates for treatment of hereditary angioedema
title_full_unstemmed Biochemical comparison of four commercially available C1 esterase inhibitor concentrates for treatment of hereditary angioedema
title_short Biochemical comparison of four commercially available C1 esterase inhibitor concentrates for treatment of hereditary angioedema
title_sort biochemical comparison of four commercially available c1 esterase inhibitor concentrates for treatment of hereditary angioedema
topic Blood Components
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4285325/
https://www.ncbi.nlm.nih.gov/pubmed/24805006
http://dx.doi.org/10.1111/trf.12678
work_keys_str_mv AT feussnerannette biochemicalcomparisonoffourcommerciallyavailablec1esteraseinhibitorconcentratesfortreatmentofhereditaryangioedema
AT kalinauwe biochemicalcomparisonoffourcommerciallyavailablec1esteraseinhibitorconcentratesfortreatmentofhereditaryangioedema
AT hofmannpeter biochemicalcomparisonoffourcommerciallyavailablec1esteraseinhibitorconcentratesfortreatmentofhereditaryangioedema
AT machnigthomas biochemicalcomparisonoffourcommerciallyavailablec1esteraseinhibitorconcentratesfortreatmentofhereditaryangioedema
AT henkelgeorg biochemicalcomparisonoffourcommerciallyavailablec1esteraseinhibitorconcentratesfortreatmentofhereditaryangioedema